This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.
The specific aims of the study are to (1) to identify clinicopathomic biomarkers from pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2) determine patterns of metastasis from primary breast cancer to other distant sites, (3) determine the rates of local recurrence in breast cancer patients, and (4) to determine if there are significant radiomic, pathomic, and clinical markers for recurrence and distant metastasis.
Study Type
OBSERVATIONAL
Enrollment
800
This is a non-interventional study.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Pathologic complete response (pCR)
Evaluating the degree of absence of residual cancer cells
Time frame: Up to 60 months
Time to local breast recurrence
Evaluating the time until a recurrence event has occurred in the breast
Time frame: Up to 60 months
Time to distant metastasis (months)
Evaluating onset of distant metastasis
Time frame: Up to 60 months
Time to death
Evaluating time to cancer-related death
Time frame: Up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.